[Form 4] LEMAITRE VASCULAR INC Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular Inc. disclosed that its president and director received new equity awards. On 12/10/2025, the insider acquired 1,694 shares of common stock as a restricted stock unit award at a price of $0, bringing total common stock beneficially owned to 23,091 shares held directly.

The insider was also granted a stock option for 10,400 shares of common stock with an exercise price of $83.66, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over three years, and include share withholding to cover taxes. The option vests 25% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		A		1,694(1)	A	$0	23,091	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$83.66	12/10/2025		A		10,400		12/01/2025(2)	12/10/2032	Common Stock	10,400	$0	10,400	D

Explanation of Responses:

1. Represents a restricted stock unit award that vests on a time-based schedule as follows: 25% of the award vests on 12/1/2026, with the balance vesting in equal annual installments over the remaining three years. This award includes a provision for the withholding of shares by the Issuer to pay the withholding taxes due on each vesting date.

2. This option is exercisable and vests over a four-year period at a rate of 25% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining three years.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LMAT report for its president and director?

The president and director of LeMaitre Vascular Inc. (LMAT) reported receiving equity compensation on 12/10/2025, consisting of 1,694 shares of common stock as a restricted stock unit award at $0 and a stock option for 10,400 shares of common stock with an exercise price of $83.66.

How many LMAT shares does the insider beneficially own after this Form 4?

Following the reported transaction, the insider beneficially owns 23,091 shares of LeMaitre Vascular Inc. common stock, held directly, as shown in Table I.

What are the vesting terms of the 1,694 LMAT restricted stock units?

The 1,694 restricted stock units vest on a time-based schedule: 25% of the award vests on 12/1/2026, with the remaining units vesting in equal annual installments over the next three years. The award allows the issuer to withhold shares on each vesting date to pay required withholding taxes.

What are the key terms of the 10,400 LMAT stock options reported?

The insider received a stock option covering 10,400 shares of LeMaitre Vascular Inc. common stock with an exercise price of $83.66 per share and an expiration date of 12/10/2032. The option vests over four years at a rate of 25% on the first anniversary of 12/01/2025, with the remaining portion vesting in equal annual installments over the following three years.

Do the LMAT equity awards require any cash payment at grant?

No cash payment was required at grant for these awards. The 1,694 restricted stock units were acquired at a price of $0, and the 10,400 stock options were also reported with a derivative security price of $0, with the option exercisable later at the stated exercise price of $83.66 per share.